Trial Profile
An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Apr 2021 Results assessing efficacy of daratumumab in patients with natural killer/T cell lymphoma by modulating the immune environment, presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 30 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results assessing daratumumab monotherapy for patients with relapsed or refractory natural killer/T-Cell lymphoma, nasal type presented at the 61st Annual Meeting and Exposition of the American Society of Hematology